Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KRYS by emailGet an email when KRYS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KRYS, unsubscribe in one click. Privacy
📣 What KRYS Says Is Next
year end · “The Company expects to enroll approximately seven patients and report interim study results before year end.”
Company press release, Aug 3, 2026 · SEC filing
in 2027 · “The Company expects to report interim study results in 2027.”
Company press release, Aug 3, 2026 · SEC filing
4Q 2026 · “The Company will share the design and associated statistical analysis of the registrational study following alignment with the FDA, which is expected in 4Q 2026, and is on track to initiate the registrational study in 2027.”
Company press release, Aug 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KRYS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KRYS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.